ArticleRedox biology2016
Tumor cells have decreased ability to metabolize H
2 registry-linked trialsOpen access · goldAbstract read
In one paragraph
Article in Redox biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 135 papers.
0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed
19.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of Pharmacological Ascorbate, Gemcitabine, and Nab-Paclitaxel for Metastatic Pancreatic Cancer (PACMAN 2.1)
XACT-Pancreas 2: Pharmacological Ascorbate, Gemcitabine, and Radiation Therapy for Pancreatic Cancer, Phase 2
Who cites it
135 citing papers in PubMed, 292 citations in OpenAlex.
- High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.Scientific reports · 2017Trial
- OCancer cell · 2017Trial
- Fractionated high-dose vitamin c sustains higher plasma trough concentrations in advanced solid tumors: a phase I clinical study.Translational oncology · 2026Article
- Pharmacological Ascorbate Restrains Epithelial-Mesenchymal Transition and Invasion in Glioblastoma Cells via Extracellular HInternational journal of molecular sciences · 2026Article
- Inflammation and RONS Dysregulation by Redox Enzymes as Mechanistic Links in HIV-1-Cancer Comorbidity.Pathogens (Basel, Switzerland) · 2026Review
- Targeting pancreatic cancer with natural compounds: molecular mechanisms, preclinical evidence, clinical perspectives, and limitations.Frontiers in pharmacology · 2026Review
- Revealing the Roles of the SH3GLB1-Hydrogen Peroxide Axis in Glioblastoma Multiforme Cells.Oncology research · 2026Article
- Polymeric Nanoparticles for Precision Tumor Immunotherapy: Rational Design Strategies and Spatiotemporal Immune Activation.International journal of nanomedicine · 2026Review
- Ruthenium coordinated nanohybrids modulate tumor microenvironment and potentiate amplified phototherapy augmented immunotherapy of hypoxic tumor.Materials today. Bio · 2025Article
- Target practice: Opportunities for therapeutic intervention in CHIP and CCUS.Blood reviews · 2025Review
- Comparative antioxidant activity of pomegranate leaf extract and derived metabolites in single and co-cultured cell lines.Scientific reports · 2025Article
- Article
- TRP channels and cancer modulation: a voyage beyond metabolic reprogramming, oxidative stress and the advent of nanotechnologies in targeted therapy.Journal of experimental & clinical cancer research : CR · 2025Review
- The STEAP4 target NQO1 mediates colon tumorigenesis.Journal of cell science · 2025Article
- High-dose vitamin C as a metabolic treatment of cancer: a new dimension in the era of adjuvant and intensive therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Unraveling the complexity of radiotherapy- and chemotherapy-induced oral mucositis: insights into pathogenesis and intervention strategies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Pharmacological Vitamin C-induced high HJournal of translational medicine · 2025Article
- The dual role of vitamin C in cancer: from antioxidant prevention to prooxidant therapeutic applications.Frontiers in medicine · 2025Review
- Rationally designed catalytic nanoplatform for enhanced chemoimmunotherapy via deploying endogenous plus exogenous copper and remodeling tumor microenvironment.Journal of nanobiotechnology · 2024Article
- Redox-active vitamin C suppresses human osteosarcoma growth by triggering intracellular ROS-iron-calcium signaling crosstalk and mitochondrial dysfunction.Redox biology · 2024Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Claire M DoskeyInterdisciplinary Graduate Program in Human Toxicology, The University of Iowa, Iowa City, IA 52242, USA.
Visarut BuranasudjaInterdisciplinary Graduate Program in Human Toxicology, The University of Iowa, Iowa City, IA 52242, USA.
Brett A WagnerFree Radical & Radiation Biology Program in the Department of Radiation Oncology, The University of Iowa, Iowa City, IA 52242, USA.
Justin G WilkesDepartment of Surgery, The University of Iowa, Iowa City, IA 52242, USA.
Juan DuDepartment of Surgery, The University of Iowa, Iowa City, IA 52242, USA.
Joseph J CullenFree Radical & Radiation Biology Program in the Department of Radiation Oncology, The University of Iowa, Iowa City, IA 52242, USA; Department of Surgery, The University of Iowa, Iowa City, IA 52242, USA; Veterans Affairs Medical Center, Veterans Affairs Medical Center, Iowa City, IA 52246, USA.
Garry R BuettnerInterdisciplinary Graduate Program in Human Toxicology, The University of Iowa, Iowa City, IA 52242, USA; Free Radical & Radiation Biology Program in the Department of Radiation Oncology, The University of Iowa, Iowa City, IA 52242, USA. Electronic address: garry-buettner@uiowa.edu.
University of Iowa · USVeterans Health Administration · US
Funding
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0MTraining CoreP42ES013661 · NIEHS · UNIVERSITY OF IOWA · PI HANS-JOACHIM LEHMLER · 2006 to 2026
$60.3MPulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5MUniversity of Iowa Surgical Oncology Training GrantT32CA148062 · NCI · UNIVERSITY OF IOWA · PI WEIGEL, RONALD J · 2010 to 2020
$3.8MThe chemical biology of pharmacological ascorbate in cancer treatmentR01CA169046 · NCI · UNIVERSITY OF IOWA · PI BUETTNER, GARRY R · 2013 to 2017
$1.6MQuantitative Redox BiologyR01GM073929 · NIGMS · UNIVERSITY OF IOWA · PI BUETTNER, GARRY R · 2008 to 2011
$1.5MPharmacological Ascorbate as a Radiosensitizer in Pancreatic CancerR01CA184051 · NCI · UNIVERSITY OF IOWA · PI CULLEN, JOSEPH J · 2015 to 2018
$1.4MNCI NIH HHS P30 CA086862NCI NIH HHS R01 CA169046NCI NIH HHS R01 CA184051NCI NIH HHS T32 CA148062NIEHS NIH HHS P30 ES005605NIEHS NIH HHS P42 ES013661NIGMS NIH HHS R01 GM073929
Abstract
Ascorbate (AscH
Indexed as
A549 CellsAnimalsAntioxidantsAscorbic AcidCatalaseCell Line, TumorHep G2 CellsHumansHydrogen PeroxideMiceOxidative StressPancreatic NeoplasmsXenograft Model Antitumor AssaysAntioxidantsAscorbic AcidCatalaseHydrogen Peroxide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT02905578ClinicalTrials.gov
NCT03541486ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.